US Stock MarketDetailed Quotes

IOBT IO Biotech

Watchlist
  • 0.931
  • -0.009-0.95%
Close Feb 14 16:00 ET
  • 0.931
  • 0.0000.00%
Post 20:01 ET
61.34MMarket Cap-0.72P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Feb 4 07:09
    NEWS
    $IO Biotech (IOBT.US)$
    IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate
    Tuesday, 4th February at 8:05 am
    – Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 –
    NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vacci...
    Trytosaveabit
    Trytosaveabit
    Jan 9 13:06
    Update Thursday 1/9/25
    $IO Biotech (IOBT.US)$ Reuters· 08:051min
    IO Biotech Completes Enrollment in Phase 2 Trial of Its Investigational, off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients With Resectable Melanoma or Head and Neck Cancer
    Jaguar8
    Jaguar8
    Jan 9 08:06
    NEWS
    $IO Biotech (IOBT.US)$
    IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
    Thursday, 9th January at 8:05 am
    -- Enrollment Completed Ahead of Schedule --
    -- Initial Data Expected in 2025 --
    NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ: IOBT), a clinical-stage biopharmaceutical company developing novel, ...
    Trytosaveabit
    Trytosaveabit
    Dec 20, 2024 07:09
    News
    $IO Biotech (IOBT.US)$ Reuters· 3 mins ago
    IO Biotech Secures up to €57.5 Million in Debt Financing From the European Investment Bank
    Jaguar8
    Jaguar8
    Nov 7, 2024 09:02
    NEWS
    $IO Biotech (IOBT.US)$
    IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
    IO Biotech announced promising Phase 2 results for its cancer vaccine IO102-IO103 combined with KEYTRUDA® in first-line metastatic lung cancer treatment. The study showed a 55% unconfirmed/48% confirmed overall response rate and 8...
Read more

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
PILOT
831175
+30.00%
XINGANJIANG
873167
+29.99%
Beijing Highlander Digital Technology
300065
+20.05%
4
Hangzhou Gaoxin Materials Technology
300478
+20.02%
5
Shijihengtong Technology
301428
+20.01%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call
Earnings Season Underway
Earnings season is here. What to know?